Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :


By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :


Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Relevium Continues to Advance Its CBD & THC Business

Anthony Varrell Anthony Varrell, StoneBridge Partners
0 Comments| November 23, 2018

The legal cannabis market is gaining significant traction all over the world and Canada has been leading the charge. Demand for cannabis products continues to increase and this is a trend that is just getting started. Although this trend is exciting, Canadian cannabis stocks have been under pressure and we have been monitoring this.

Last month, we highlighted Relevium Technologies (RLV.V) (RLLVF) as a company that is capitalizing on this opportunity and today, we wanted to issue an update on the Canadian cannabis company. 

Earlier this year, Relevium announced its intention to enter the medical cannabis market and is focused on the production of organic medical cannabis through its wholly-owned subsidiary, Biocannabix Health (BCX). The company has been nothing short of an execution story and has signed a lease agreement for a 93,000 sq. ft., vertically integrated facility that has received the necessary approvals by the City of St-Laurent, Quebec.

BCX is focused on attaining a Cultivation License from Health Canada and will be leveraging PipeDreemz and lead consultant George Routhier who has a remarkable 100% success rate with ACMPR licensing from Health Canada. This would be a major catalyst for the company and we are monitoring this opportunity.

Although Relevium has been working on being granted a Cultivation License, the company has been actively capitalizing on the cannabidiol (CBD) opportunity. Last month, Relevium announced plans to increase the number of CBD products being sold on and we are bullish on this. 

During the summer, Relevium expanded its focus to Europe and signed a supply agreement with Plena Global Holdings to supply full spectrum CBD oil to the company’s supply chain partners in Europe starting in January. These agreements represent a significant opportunity as it will improve brand awareness in a major emerging market. Relevium recently announced a line of hemp derived organic CBD infused products under the LeefyLyfe brand for the European market and we are bullish on the growth prospects heading into 2019.

Forms Strategic Partnership with Holistic Industries

Earlier this month, Relevium executed a letter of intent to form a partnership with Holistic Industries to jointly develop Biocannabix Health Corp, the pediatric and geriatric focused biopharma subsidiary of Relevium Technologies. This is a significant relationship and we are favorable on opportunity to create value through this strategic partnership.

Holistic Industries adds significant value to Biocannabix and is licensed in four states and the District of Columbia to grow, process, develop and retail top quality and safe medical products to the market. Holistic Industries major contributions are expected to include knowledge transfer for growing organically, management of genetic strains for specific health purposes, processing technology as well as existing formulations from their trusted Liberty product portfolio. Although a definitive agreement is only expected within the next 60 days, both companies are already cooperating in the design and capability development of the facilities in Montreal.

Biocannabix Health is being structured to be a leading Biopharma company focused on research and development of cannabis derived nutraceuticals, pharmaceuticals and medicinal foods. In order to ensure focus and support maximum value creation for shareholders, Relevium is considering the eventual spinoff of Biocannabix as a focused and separate publicly traded company.   

Makes Strategic Investment in

Last month, Relevium executed a binding letter of intent for a strategic investment into for an initial 25% equity position. Cannakids is a leader in the medical cannabis patient research and consumer product development for pediatric and adult applications. The company distributes its products through a growing and extensive network of licensed retail locations across California, all while working on both national and international expansion plans.

As part of the strategic investment, Relevium obtained the exclusive Canadian license for Cannakids, which will allow Relevium to build upon the existing infrastructure and standard operating procedures to launch the brand across Canada and to expand Cannakids’ growing patient network to support ongoing research for cancer, autism and epilepsy, amongst other specialized applications.

Cannakids’ patient research and product development has been centered primarily around pediatric applications, but the company services and guides patients of all ages. Counting with a database of thousands of patients, CK leverages a network of trained nursing staff, pediatric and adult dosing experts, medical doctors and leading researchers in the United States and Israel.

The objective for BCX was to build a fully integrated biopharma company with control over plant genetics and develop a true understanding, at the molecular level, about the beneficial use, formulation and dosage for pediatric and geriatric applications. This investment supports this initiative and we will monitor how the team executes on this opportunity.

A Company Worth Watching

Although Relevium has significant advanced its fundamental story and has been executing flawlessly, the shares have been trading lower and this is company to watch. Relevium has a number of catalysts for growth and we are favorable on the growth prospects heading into 2019.

Relevium represents a multi-faceted growth opportunity and we will monitor how the team continues to execute. The leverage to the CBD market and the focus on the organic opportunity are significant and makes this a differentiated opportunity.

We think that the market underappreciates the growth potential and will monitor how Relevium continues to execute. To stay up to date with Relevium Technologies, please email

Interested in these industries and sectors?

Receive investor kits and email updates from Stockhouse and directly from these companies.

Metals & Mining

Interested in these industries and sectors?

You are already a member! Please enter your password to sign in.


No comments yet. Be first to comment!

Leave a Comment

You must be logged in to access this feature.


Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.